Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Free Cash Flow (2018 - 2025)

Neurogene (NGNE) has disclosed Free Cash Flow for 5 consecutive years, with -$20.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow fell 29.18% year-over-year to -$20.4 million, compared with a TTM value of -$78.3 million through Sep 2025, down 45.46%, and an annual FY2024 reading of -$71.3 million, down 38.71% over the prior year.
  • Free Cash Flow was -$20.4 million for Q3 2025 at Neurogene, down from -$18.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$15.8 million in Q3 2024 and bottomed at -$21.8 million in Q1 2024.